From: Improving clinical trials using Bayesian adaptive designs: a breast cancer example
Design | Trial conclusion | Duration (months) | Sample size | Hazard ratio (95% CI) |
---|---|---|---|---|
Original trial | H0 not rejected | 53.0 recruitment + 91.2 follow-up | 235 | 1.17 (0.90, 1.52) |
Small sample size | ||||
Posterior | Early futility | 69.9 | 233 | 1.14 (0.85, 1.52) |
PPS | Early futility | 50.6 | 214 | 1.03 (0.71, 1.48) |
CPS | Early futility | 43.2 | 164 | 1.00 (0.66, 1.52) |
Goldilocks | Early futility | 50.6 | 214 | 1.03 (0.71, 1.48) |
PPBS | Early futility | 42.3 | 158 | 0.98 (0.64, 1.50) |
High power | ||||
Posterior | Inconclusive | 120.5 | 233 | 1.17 (0.90, 1.53) |
PPS | Early futility | 52.4 | 228 | 1.10 (0.77, 1.58) |
CPS | Early futility | 47.8 | 189 | 1.00 (0.68, 1.47) |
Goldilocks | Early futility | 52.4 | 228 | 1.10 (0.77, 1.58) |
PPBS | Early futility | 47.8 | 189 | 1.00 (0.68, 1.47) |